Telemedicine Influence in the Follow up of the Type 2 Diabetes Patient
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00527254|
Recruitment Status : Completed
First Posted : September 10, 2007
Last Update Posted : September 10, 2007
|Condition or disease||Intervention/treatment|
|Type 2 Diabetes Telemedicine Self Monitoring Blood Glucose Primary Care||Device: Telemedicine system|
The UKPDS study in type 2 diabetes and the DCCT in type 1, showed that intensive blood glucose control and the following HBA1c decrease were associated with a decrease of diabetic complications. Introducing telecontrol elements in the real time follow up of the patients, should help to know continuously patient blood glucose profile and add if necessary immediately therapeutical variations, to maintain HbA1c levels as low as possible.
The study compares type 2 diabetes patients performing self monitoring of blood glucose, followed up by their family doctor in their primary care unit with the extra support of a real time teleassistance system with type 2 diabetes patients performing self monitoring of blood glucose, followed up by their family doctor in their primary care unit.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||328 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Study Start Date :||October 2003|
|Study Completion Date :||June 2005|
|No Intervention: Control group|
|Active Comparator: Telemedicine group||
Device: Telemedicine system
Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
- HBA1c Glycosylated hemoglobin [ Time Frame: one year for every patient ]
- Blood glucose, Total Cholesterol, HDL Cholesterol,LDL Cholesterol, Triglycerides, BMI, systolic and diastolic blood pressure and system adherence [ Time Frame: one year for every patient ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00527254
|Province of Malaga Health Department|
|Málaga, Spain, 29001|
|Principal Investigator:||Maria Isabel Rodríguez Idígoras, Doctor||Málaga Health Department (Junta de Andalucia)|